We timed MYC amplification in Ovarian cancers (OV; gained in 102/111 samples including gains by WGD and CN-LOH) and Breast cancers (BRCA; amplified in 156/196 samples, including gains by WGD and CN-LOH). This evidence concerns the gene MYC and ovarian cancer.